Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Equity Bottom-Up

<p>Ocugen’s modifier gene therapy (MGT) platform is designed to regulate gene expression to restore visual function across both genetically diverse inherited retinal diseases (IRDs) and retinal conditions with wider prevalence such as geographic atrophy (GA) associated with dry age-related macular degeneration (AMD). Lead candidate OCU400 is in Phase III studies for retinitis pigmentosa (RP), with a potential FDA biologics license application (BLA) in 2026 and commercialisation in 2027.</p>

Ocugen’s modifier gene therapy (MGT) platform is designed to regulate gene expression to restore visual function across both genetically diverse inherited retinal diseases (IRDs) and retinal conditions with wider prevalence such as geographic atrophy (GA) associated with dry age-related macular degeneration (AMD). Lead candidate OCU400 is in Phase III studies for retinitis pigmentosa (RP), with a potential FDA biologics license application (BLA) in 2026 and commercialisation in 2027.

Ocugen — Novel cell therapies for retinal diseases

United States

Ocugen, Inc. operates as a clinical stage biopharmaceutical company. The Company offers products for improving the body's ability to regenerate healthy cartilage, joint function, and prevention of degenerative diseases. Ocugen serves patients and orthopedist throughout the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ocugen (OCGN US)

Ocugen — Novel cell therapies for retinal diseases

Ocugen’s modifier gene therapy (MGT) platform is designed to regulate gene expression to restore visual function across both genetically diverse...

Edison Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)